JP7461663B2 - 眼疾患の処置方法 - Google Patents

眼疾患の処置方法 Download PDF

Info

Publication number
JP7461663B2
JP7461663B2 JP2021560499A JP2021560499A JP7461663B2 JP 7461663 B2 JP7461663 B2 JP 7461663B2 JP 2021560499 A JP2021560499 A JP 2021560499A JP 2021560499 A JP2021560499 A JP 2021560499A JP 7461663 B2 JP7461663 B2 JP 7461663B2
Authority
JP
Japan
Prior art keywords
beauvericin
diabetic retinopathy
eye disease
administration
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021560499A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022528566A5 (enExample
JP2022528566A (ja
Inventor
リー，ショーエイ－ション
スー，ミン－ジャイ
リン，ルン－ジェ
スー，チャオ－ミン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ZIH YUAN TANG BIOTECHNOLOGY Co Ltd
Original Assignee
ZIH YUAN TANG BIOTECHNOLOGY Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ZIH YUAN TANG BIOTECHNOLOGY Co Ltd filed Critical ZIH YUAN TANG BIOTECHNOLOGY Co Ltd
Publication of JP2022528566A publication Critical patent/JP2022528566A/ja
Publication of JP2022528566A5 publication Critical patent/JP2022528566A5/ja
Application granted granted Critical
Publication of JP7461663B2 publication Critical patent/JP7461663B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/15—Depsipeptides; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2021560499A 2019-04-03 2020-04-01 眼疾患の処置方法 Active JP7461663B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962828616P 2019-04-03 2019-04-03
US62/828,616 2019-04-03
US201962899279P 2019-09-12 2019-09-12
US62/899,279 2019-09-12
PCT/CN2020/082765 WO2020200241A1 (en) 2019-04-03 2020-04-01 Method for treating ocular diseases

Publications (3)

Publication Number Publication Date
JP2022528566A JP2022528566A (ja) 2022-06-14
JP2022528566A5 JP2022528566A5 (enExample) 2022-09-06
JP7461663B2 true JP7461663B2 (ja) 2024-04-04

Family

ID=72662774

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021560499A Active JP7461663B2 (ja) 2019-04-03 2020-04-01 眼疾患の処置方法

Country Status (7)

Country Link
US (1) US11033603B2 (enExample)
EP (1) EP3946414B1 (enExample)
JP (1) JP7461663B2 (enExample)
CN (1) CN113795268B (enExample)
SG (1) SG11202110659SA (enExample)
TW (1) TWI818168B (enExample)
WO (1) WO2020200241A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI788083B (zh) * 2021-11-03 2022-12-21 葡萄王生技股份有限公司 蟬花菌絲體活性物質用於治療黃斑部病變之用途
US20240316144A1 (en) * 2023-03-20 2024-09-26 ZIH YUAN TANG Biotechnology Co, Ltd. Pharmaceutical composition and method for inhibiting angiogenesis

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140371158A1 (en) 2013-06-14 2014-12-18 Georgia Regents University Beauvericin compositions and methods thereof for inhibiting the hsp90 chaperone pathway

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0327316A (ja) * 1989-06-23 1991-02-05 Kitasato Inst:The 高脂血症治療剤
BRPI0615974A2 (pt) * 2005-07-27 2011-05-31 University Of Florida Research Foundation, Inc., uso de choque térmico para tratar uma doença ocular em um indivìduo, método para recrutar uma célula-tronco para um tecido ocular de um indivìduo com necessidade da mesma, uso de choque térmico para tratar uma doença ou um distúrbio ocular em um indivìduo com necessidade do mesmo, uso de choque térmico para regenerar a retina em um indivìduo com necessidade do mesmo, uso de choque térmico para reparar os danos ao epitélio pgmentar da retina em um indivìduo com necessidade do mesmo, uso de choque térmico para tratar a degeneração macular em um indivìduo com necessidade do mesmo, composição farmacêutica para o recrutamento de células-tronco, composição farmacêutica para recrutamento de células-tronco em um tecido ocular, kit e método para identificar um agente que aumenta o recrutamento de células-tronco em um tecido ocular
CN101669939A (zh) * 2009-09-22 2010-03-17 中山大学 恩镰孢菌素类化合物在制备抗耐药结核菌药物中的应用
US20140275091A1 (en) * 2013-03-15 2014-09-18 Coyote Pharmaceuticals, Inc. Ocular formulations comprising geranylgeranylacetone derivatives for intraocular delivery
CN109200066A (zh) * 2017-07-07 2019-01-15 葡萄王生技股份有限公司 蝉花活性物质及其用于预防、延缓或治疗白内障的用途

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140371158A1 (en) 2013-06-14 2014-12-18 Georgia Regents University Beauvericin compositions and methods thereof for inhibiting the hsp90 chaperone pathway

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Journal of Natural Products，2007年，Vol.70, Issue 2，p.227-232
Toxicology Letters，2014年，Vol.231，p.9-16

Also Published As

Publication number Publication date
US11033603B2 (en) 2021-06-15
EP3946414A1 (en) 2022-02-09
CA3132137A1 (en) 2020-10-08
WO2020200241A1 (en) 2020-10-08
EP3946414B1 (en) 2025-12-03
CN113795268A (zh) 2021-12-14
KR20210149087A (ko) 2021-12-08
JP2022528566A (ja) 2022-06-14
TW202102252A (zh) 2021-01-16
CN113795268B (zh) 2025-04-08
TWI818168B (zh) 2023-10-11
US20200316165A1 (en) 2020-10-08
EP3946414A4 (en) 2022-12-07
EP3946414C0 (en) 2025-12-03
SG11202110659SA (en) 2021-10-28

Similar Documents

Publication Publication Date Title
Audren et al. Intravitreal triamcinolone acetonide for diffuse diabetic macular edema: phase 2 trial comparing 4 mg vs 2 mg
CN114786480B (zh) 使用内皮素受体拮抗剂治疗眼部疾病
US11951115B2 (en) Methods of treating retinal vasculopathies
CN103705524A (zh) 具有二氟泼尼酯的黄斑水肿治疗用滴眼剂
US8097640B2 (en) Prophylactic or therapeutic agent for diabetic maculopathy
TWI818168B (zh) 治療眼疾的方法
Kaneko et al. Increased retinal thinning after combination of internal limiting membrane peeling and silicone oil endotamponade in proliferative diabetic retinopathy
Giannico et al. Effects of prostaglandin analogs on blood flow velocity and resistance in the ophthalmic artery of rabbits
KOLLARITS et al. Norepinephrine therapy of ischemic optic neuropathy
CA3132137C (en) Method for treating ocular diseases
CN114588236B (zh) 组合物在制备药物中的用途
WO2022251543A1 (en) Use of complement factor d inhibitor for treatment of geographic atrophy secondary to age-related macular degeneration
JPH11349486A (ja) 糖尿病性網膜症治療のためのスロデキサイドを含有する医薬
Esquenazi Cystoid macular edema in a pseudophakic patient after switching from latanoprost to BAK-free travoprost
Jovanović et al. Intravitreal bevacizumab injection alone or combined with macular photocoagulation compared to macular photocoagulation as primary treatment of diabetic macular edema.
RU2284812C1 (ru) Способ лечения пролиферативной витреоретинопатии
Schilling et al. An elusive case of cystoid macular edema
Lin et al. Low-dose Intravitreal Triamcinolone Combined with Vitrectomy for Proliferative Diabetic Retinopathy
EP3331517B1 (fr) Utilisation d'hydroxycarbamide pour prevenir la non-perfusion retinienne
Farag et al. Study of Structural Changes in Diabetic Macular Edema by Spectral Domain Optical Coherent Tomography after Intravitreal Injection of Triamcinolone Acetonide
CN117897168A (zh) 治疗视网膜血管病变的方法
WO2019087189A1 (en) A method for improving ocular blood flow
Sanabria et al. Atypical myopic retinoschisis
Pandya et al. Clinical challenges

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220829

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220829

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20230712

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230718

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20231017

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231215

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240220

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240315

R150 Certificate of patent or registration of utility model

Ref document number: 7461663

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150